Compare · CLDX vs ORKA
CLDX vs ORKA
Side-by-side comparison of Celldex Therapeutics Inc. (CLDX) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDX and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.63B, about 1.6x CLDX ($2.25B).
- Over the past year, CLDX is up 38.3% and ORKA is up 378.2% - ORKA leads by 339.9 points.
- ORKA has hit the wire 11 times in the past 4 weeks while CLDX has been quiet.
- CLDX has more recent analyst coverage (21 ratings vs 11 for ORKA).
- Company
- Celldex Therapeutics Inc.
- Oruka Therapeutics Inc.
- Price
- $28.64-4.36%
- $60.12-3.49%
- Market cap
- $2.25B
- $3.63B
- 1M return
- -16.76%
- -13.81%
- 1Y return
- +38.33%
- +378.24%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 11
- Recent ratings
- 21
- 11
Celldex Therapeutics Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Latest CLDX
- SEC Form SCHEDULE 13G filed by Celldex Therapeutics Inc.
- SEC Form 10-Q filed by Celldex Therapeutics Inc.
- Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celldex Reports First Quarter Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13G/A filed by Celldex Therapeutics Inc.
- SEC Form DEF 14A filed by Celldex Therapeutics Inc.
- Celldex Therapeutics upgraded by Barclays with a new price target
- Celldex to Present at Upcoming Investor Conference
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SEC Form 424B5 filed by Celldex Therapeutics Inc.
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)